DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Withdrawn Rejection
The rejection of claim(s) 1, 3-4, and 26-30, under 35 U.S.C. 103 as being unpatentable over Srivastava (Srivastava et al. Journal of Immunological Methods 389:61-68, 2013) in further view of Choudhary (US 2015/0159134 pub date:6/11/2015; effectively filed: 12/11/2013), is withdrawn. Applicant’s argument regarding “95% of said RPE cells of the population” is found persuasive. Further, the combined art does not teach or suggest “qualifying whether…RPE..cell population is suitable for treating a retinal disease or disorder” and does not teach or suggest, “qualifying said population as being a suitable therapeutic for treating the retinal disease or disorder when at least 95% of said RPE cells of the population co-express CRALBP and PMEL17”.
Claim Rejections - 35 USC § 112
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1, 3-4, and 26-30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Independent claim 1 is indefinite because the claims as amended not longer provide a relationship between the measuring of PEDF and VEGF and qualifying said population as being suitable as a therapeutic. Step (iii) measures PEDF and VEGF and requires the RPE cells of the population to be polarize. Step (iv) qualifies the RPE cell of the population as a suitable therapeutic based upon co-expression of CRALBP and PMEL17 expression but does not the measurements from step (iii). As such, it is not apparent how the measuring step of (iii) is involved in qualifying said population as being a suitable therapeutic.
Claims 3-4, and 26-30 depend upon claims and as such also comprise the indefinite issues of claim 1.
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCIA STEPHENS NOBLE whose telephone number is (571)272-5545. The examiner can normally be reached M-F 9-5:30.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
MARCIA S. NOBLE
Primary Examiner
Art Unit 1632
/MARCIA S NOBLE/ Primary Examiner, Art Unit 1632